Autonomix Medical Receives U.S. Patent For Precision Cardiac Neuromodulation And Feedback Therapy

Autonomix Medical, Inc., a medical device innovator focused on precision nerve-targeted treatments, announced that the U.S. Patent and Trademark Office (USPTO) has granted U.S. Patent No. 12,369,852, titled “Controlled and Precise Treatment of Cardiac Tissues.” The patent covers advanced systems and methods that detect autonomic and cardiac signals, map target regions, and deliver closed-loop therapy for precise treatment of cardiac tissues through neuromodulation, denervation, and ablation.

“We are pleased to further reinforce our intellectual property around our technology. The autonomic nervous system plays a major role in regulating and maintaining normal cardiac activity. Cardiac disease is often treated by sympathetic beta-receptor blockade, which affects all cells and organs of the body and often leads to unwanted and intolerable side effects. Our breakthrough technology has the potential to provide precision nerve-targeted therapies that could transform treatment in high-growth areas of cardiology, including renal denervation for hypertension, arrhythmia management, heart failure, and refractory angina, offering new solutions with fewer complications,” commented Brad Hauser, CEO of Autonomix.

The newly issued patent strengthens Autonomix’s position in the field of feedback-guided cardiac therapies. It details systems capable of identifying and monitoring neural activity near targeted heart regions, allowing highly accurate treatment and mapping of tissues. The innovation is applicable to a range of cardiovascular conditions, including atrial and ventricular arrhythmias, ischemia, refractory angina, coronary spasm, heart failure, hypertension, and modulation of plaque or inflammation, potentially minimizing reliance on systemic medications such as beta-blockers.

With this patent, Autonomix expands its intellectual property portfolio and reinforces its first-in-class therapeutic platform, which has potential across several high-need medical areas. Beyond cardiology and resistant hypertension, the company’s precision nerve-mapping and treatment technology also shows promise in interventional pain management, pulmonary, and gastrointestinal disorders, underscoring its broad clinical and commercial potential.